TDC
QGENF

Thompson Davis & Co’s QIAGEN NV QGENF Stock Holding History

Thompson Davis & Co’s Portfolio QGENF Stock Details QGENF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,375
Closed -$38K – 1289
2015
Q4 		$38K Buy
1,375
+125
+10% +$3.46K 0.05% 307
2015
Q3 		$32K Buy
+1,250
New +$32K 0.04% 348

Other funds holding QGENF

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
MNA
Manning & Napier Advisors Fairport, New York $7.09B AUM 17.35% 1-Year Est. Return
HJGA
Hardman Johnston Global Advisors Stamford, Connecticut $2.1B AUM 41.89% 1-Year Est. Return
CRM
Cramer Rosenthal McGlynn Stamford, Connecticut $1.36B AUM 31.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Thompson Davis & Co's QGENF Position: Q1 2016 in Review

Thompson Davis & Co sold out of QIAGEN NV (QGENF) in Q1 2016, closing a stake of 1,375 shares — an estimated $38K sold.

Thompson Davis & Co first reported a position in QGENF in Q3 2015 and held it in 2 quarters. The position peaked at $38K in Q4 2015. 201 funds tracked by Wall St. Rank hold QGENF as of Q1 2016.

  • Thompson Davis & Co reported no remaining QIAGEN NV position as of Q1 2016 after selling out during the quarter.
  • Thompson Davis & Co sold 1,375 QIAGEN NV shares in Q1 2016, an estimated $38K.
  • Thompson Davis & Co first reported a position in QIAGEN NV in Q3 2015 and held it in 2 quarters.
  • Thompson Davis & Co's QIAGEN NV position peaked at $38K in Q4 2015.
  • 201 funds tracked by Wall St. Rank held QIAGEN NV as of Q1 2016.

Based on Thompson Davis & Co's 13F filing for Q1 2016, filed 2 May 2016.